Src

Src kinase family is a family of non-receptor tyrosine kinases that includes nine members: Src, Yes, Fyn, and Fgr, forming the SrcA subfamily, Lck, Hck, Blk, and Lyn in the SrcB subfamily, and Frk in its own subfamily. Frk has homologs in invertebrates such as flies and worms, and Src homologs exist in organisms as diverse as unicellular choanoflagellates, but the SrcA and SrcB subfamilies are specific to vertebrates. Src family kinases contain six conserved domains: a N-terminal myristoylated segment, a SH2 domain, a SH3 domain, a linker region, a tyrosine kinase domain, and C-terminal tail.

Cat. No.	Product name	CAS No.	Purity
T2610	BMS-599626	714971-09-2	98.73%
T2610	BMS-599626 has been used in trials studying the treatment of Cancer, Metastases, and HER2 or EGFR Expressing Advanced Solid Malignancies.
T10583	Bosutinib D8	T10583	98%
T10583	Bosutinib D8 is a deuterium-labeled Bosutinib. Bosutinib (SKI-606) is a dual Src/Abl inhibitor (IC50s: 1.2 nM/1 nM).
T14074	A-770041	869748-10-7	98%
T14074	A-770041 is selective and orally active Src-family Lck inhibitor, and the other Src family kinase involved in T-cell signaling. A-770041 is a 147 nM inhibitor of...
T11752	Keap1-Nrf2-IN-1	2232112-72-8	98%
T11752	Keap1–Nrf2 IN-1 activates Nrf2-regulated cytoprotective response and antagonizes acetaminophen-induced liver injury both in cellular and in vivo models. Keap1–Nr...
T10784	CH6953755	2055918-71-1	98%
T10784	CH6953755 is a potent, orally active and selective inhibitor of YES1 kinase (IC50: 1.8 nM). It inhibits YES1 kinase, leading to antitumor activity against YES1 G...
T10206	A 419259	364042-47-7	98%
T10206	A 419259 is a pyrrolo-pyrimidine inhibitor, designed to enhance selectivity towards the Src family (IC50s: 9 nM, <3 nM and <3 nM for Src, Lck and Lyn).
TN3139	5α-Hydroxycostic acid	132185-83-2	98%
TN3139	5alpha-Hydroxycostic acid possesses anti-angiogenic ability by interfering the VEGF- and Ang2-related pathways, and it may be a good drug candidate.
T15674	Tirbanibulin dihydrochloride	1038395-65-1	98%
T15674	Tirbanibulin is an inhibitor of Src that targets the peptide substrate site of Src (GI50: 9-60 nM in cancer cell lines).
T14055	5Z-7-Oxozeaenol	253863-19-3	98%
T14055	5Z-7-Oxozeaenol, a natural anti-protozoan compound from fungal origin, acting as a potent irreversible and selective inhibitor of TAK1 and VEGF-R2, with IC50s of...
T13186L	TL02-59 dihydrochloride	2415263-06-6	98%
T13186L	TL02-59 dihydrochloride is an orally active inhibitor of Src-family kinase Fgr (IC50: 0.03 nM).
T22303	Dasatinib hydrochloride	854001-07-3	99.98%
T22303	Dasatinib hydrochloride (BMS-354825) hydrochloride is a highly potent, ATP competitive, orally active dual Src/Bcr-Abl inhibitor with potent antitumor activity. ...
T4301	AD80	1384071-99-1	99.9%
T4301	AD80, a multikinase inhibitor, inhibits RET, RAF, SRCand S6K, with greatly reduced mTOR activity.
T1448	Dasatinib	302962-49-8	99.89%
T1448	Dasatinib is a potent inhibitor of the Bcr-Abl and Src family (IC50s: 0.6, 0.8, 79 and 37 nM for Abl, Src, c-Kit, and c-KitD816V, respectively).
T2341	KW-2449	1000669-72-6	99.89%
T2341	KW-2449 is a multiple-targeted inhibitor, mostly for Flt3 (IC50: 6.6 nM), modestly effective to Bcr-Abl, FGFR1, and Aurora A; little inhibitory on PDGFRβ, IGF-1R...
T6680	Staurosporine	62996-74-1	99.87%
T6680	Staurosporine is a potent PKC inhibitor for PKCα/γ/η (IC50: 2/5/4 nM), less potent to PKCε (73 nM), PKCδ (20 nM) and little action to PKCζ (1086 nM).
T2327	Pelitinib	257933-82-7	99.86%
T2327	Pelitinib (EKB-569) is an effective irreversible EGFR inhibitor (IC50: 38.5 nM).
T4071	Repotrectinib	1802220-02-5	99.86%
T4071	TPX-0005 is a potent ALK/ROS1/TRK inhibitor, with IC50 of 1.01 nM, 5.3 nM, 1.08 nM and 1.26 nM for WT ALK, SRC, ALK L1196M and ALK G1202R, respectively.
T3935	1-Naphthyl PP1	221243-82-9	99.85%
T3935	1-Naphthyl PP1 is a selective src inhibitor(v-Src and c-Fyn, c-Abl, CDK2 and CAMK II with IC50s of 1.0, 0.6, 0.6, 18 and 22 μM, respectively)
T0152	Bosutinib	380843-75-4	99.84%
T0152	Bosutinib is a synthetic quinolone derivative and dual kinase inhibitor that targets both Abl (IC50: 1 nM) and Src (IC50: 1.2 nM) kinases.
T2640	Rebastinib	1020172-07-9	99.84%
T2640	DCC-2036 (Rebastinib) is a conformational control Bcr-Abl inhibitor for Abl1(WT, IC50: 0.8 nM) and Abl1(T315I, IC50: 4 nM), also inhibits LYN, SRC, HCK, FGR, FLT...